Welcome to our dedicated page for Champions Oncolo SEC filings (Ticker: CSBR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
R&D milestones, collaboration revenue splits, and non-cash stock-based compensation crowd every Champions Oncology filing. If hunting through 200+ pages to track pipeline progress feels daunting, our AI-powered platform turns that complexity into clarity. StockTitan instantly converts dense SEC jargon into plain-English takeaways鈥攑erfect whether you need the latest Champions Oncology insider trading Form 4 transactions or want its Tumorgraft鈩� revenue breakout without decoding footnotes.
All core documents are here the moment they hit EDGAR. Skim an AI summary of the Champions Oncology annual report 10-K simplified, drill into a Champions Oncology quarterly earnings report 10-Q filing, or set alerts for every Champions Oncology Form 4 insider transactions real-time. Curious about sudden leadership changes? The next Champions Oncology 8-K material events explained will appear with context, showing how a new study read-out might shift revenue guidance.
Use cases our users rely on:
- Compare quarter-over-quarter R&D spend in seconds using Champions Oncology earnings report filing analysis.
- Monitor Champions Oncology executive stock transactions Form 4 before pivotal trial updates.
- Review the Champions Oncology proxy statement executive compensation to evaluate pay vs. performance.
- Save hours understanding Champions Oncology SEC documents with AI rather than parsing scientific appendices yourself.
No more manual searches鈥攋ust comprehensive coverage, real-time updates, and expert insights that make Champions Oncology SEC filings explained simply.
Champions Oncology (CSBR) filed an 8-K disclosing a leadership change effective 25 Aug 2025. Director Robert Brainin, 54, will become Chief Executive Officer while retaining his board seat. Brainin brings 25+ years of life-science experience, most recently as Chief Business Officer & EVP at Veracyte, and previously held senior roles at Genuity Science, Illumina, Thermo Fisher and Life Technologies.
Key employment terms (Exhibit 10.1): $500,000 annual base salary, discretionary bonus targeted at 75% of salary, and 700,000 stock options鈥�225,000 vesting over four years and 475,000 vesting on performance milestones. No family relationships or related-party transactions were reported.
Current CEO Ronnie Morris, M.D., will move to Executive Chairman to support the transition; Chairman Joel Ackerman will resume duties as Board Director. Related press release is filed as Exhibit 99.1.
FAQ
What is the current stock price of Champions Oncolo (CSBR)?
What is the market cap of Champions Oncolo (CSBR)?
What is the primary focus of Champions Oncology?
What business segments does Champions Oncology operate?
How does Champions Oncology differentiate itself in the oncology research industry?
What technological platforms are central to Champions Oncology鈥檚 services?
Who are the main customers of Champions Oncology?
Are there any recent strategic collaborations involving Champions Oncology?
How does Champions Oncology support personalized cancer treatment?
What role do bioanalytical and diagnostic services play in the company鈥檚 strategy?
